Profile
Gabriele Elbl worked as Head-Regulatory Affairs at MorphoSys AG from 2013 to 2018.
Prior to that, she was SVP-Regulatory Affairs & Quality Control at Heidelberg Pharma AG in 2012.
She also served as Vice President-Global Regulatory Affairs at Nordic Nanovector ASA. Elbl holds a doctorate degree from Ludwig-Maximilians-Universität München.
Former positions of Gabriele Elbl
Companies | Position | End |
---|---|---|
MORPHOSYS AG | General Counsel | 2018-09-30 |
THOR MEDICAL | General Counsel | - |
HEIDELBERG PHARMA AG | General Counsel | - |
Training of Gabriele Elbl
Ludwig-Maximilians-Universität München | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
HEIDELBERG PHARMA AG | Health Technology |
MORPHOSYS AG | Health Technology |
Private companies | 1 |
---|---|
Nordic Nanovector ASA
Nordic Nanovector ASA Pharmaceuticals: MajorHealth Technology Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The firm offers the Betalutin which is an antibody radionuclide conjugates for the treatment of non-Hodgkin lymphoma. It operates through the following geographical segments: Norway, Switzerland, and the United Kingdom. The company was founded by Roy Hartvig Larsen, Oyvind Sverre Bruland, and Jostein Dahle on July 2, 2009 and is headquartered in Oslo, Norway. | Health Technology |
- Stock Market
- Insiders
- Gabriele Elbl